Arvinas (ARVN) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Arvinas (ARVN) has outperformed CorMedix (CRMD) over the past year, losing 26.8% versus a loss of 28.7%. Over five years, CRMD leads with a +52.8% price change compared with -91.8% for ARVN. CorMedix is the larger company by market cap ($565.9 million vs $449.7 million), about 1.3 times the size.
On valuation, CorMedix trades at a lower trailing P/E (3.5x vs 26.8x for Arvinas). CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -30.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | CRMD |
|---|---|---|
| Share price | $6.97 | $7.26 |
| Market cap | $449.71M | $565.88M |
| 1-day change | -2.65% | -2.68% |
| YTD return | -41.23% | -37.58% |
| 1-year return | -26.79% | -28.68% |
| 5-year return | -91.79% | +52.84% |
| P/E ratio (TTM) | 26.81 | 3.54 |
| Forward P/E | — | 20.74 |
| EPS (TTM) | $0.26 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $311.71M |
| Revenue growth (YoY) | -0.30% | +617.03% |
| Net income (latest FY) | $-80.80M | $163.06M |
| Gross margin | — | 88.46% |
| Operating margin | -45.13% | 48.17% |
| Net margin | -30.77% | 52.31% |
| 52-week high | $14.51 | $13.02 |
| 52-week low | $6.74 | $6.13 |
| Distance from 52-week high | -51.96% | -44.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +99.86% | +111.16% |
| Average volume | 800.32K | 1.11M |
| Shares outstanding | 64.52M | 77.94M |
| Employees | 246 | 191 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Arvinas trades at a higher earnings multiple (26.8x vs 3.5x trailing P/E).
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -30.8 cents for Arvinas.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -0.30%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
ARVN vs CRMD FAQ
Which is bigger, Arvinas or CorMedix?
CorMedix (CRMD) is larger, with a market capitalization of $565.88M compared with $449.71M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or CRMD?
ARVN returned -26.79% over the past 12 months, compared with -28.68% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARVN or CRMD?
CRMD has the lower trailing P/E at 3.5, versus 26.8 for ARVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arvinas and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.